SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

Months after the latest losartan recall and more than a year after drug companies first started pulling bulk lots of angiotensin II receptor blockers (ARB) from pharmacy shelves, the FDA has issued a statement updating the American public on the scope of the situation.

Anxiety about rejection and abandonment in close relationships could be a risk factor for cardiovascular disease, a study out of Concordia University has found.

An editorial published in the latest issue of The Lancet suggests physicians might make quicker progress toward reducing global levels of uncontrolled hypertension if they reframe the condition as part of a patient’s whole health profile, rather than as an isolated disease.

Rates of hypertension have been climbing in the U.S. in recent years, according to an analysis by Blue Cross Blue Shield, and they’re growing fastest among millennials and adults in their mid-thirties and forties.

Heart disease deaths are on the rise in the U.S., according to research published in the Journal of the American Medical Association Aug. 27—and they have been for almost a decade.

Oregon Health & Science University will resume its heart transplant services this month after nearly a year of inactivity, the university announced Aug. 26.

Early anticoagulation after bioprosthetic aortic valve replacement didn’t result in adverse clinical events or significantly affect aortic valve hemodynamics in a recent analysis of 4,832 heart patients, but it was linked to lower stroke rates in cases of SAVR.